| Literature DB >> 26314280 |
Juli Rodriguez Bagó1, Kevin T Sheets1, Shawn D Hingtgen2.
Abstract
Cancers of the brain remain one of the greatest medical challenges. Traditional surgery and chemo-radiation therapy are unable to eradicate diffuse cancer cells and tumor recurrence is nearly inevitable. In contrast to traditional regenerative medicine applications, engineered neural stem cells (NSCs) are emerging as a promising new therapeutic strategy for cancer therapy. The tumor-homing properties allow NSCs to access both primary and invasive tumor foci, creating a novel delivery platform. NSCs engineered with a wide array of cytotoxic agents have been found to significantly reduce tumor volumes and markedly extend survival in preclinical models. With the recent launch of new clinical trials, the potential to successfully manage cancer in human patients with cytotoxic NSC therapy is moving closer to becoming a reality.Entities:
Keywords: Cancer therapy; Drug delivery; Gene therapy; Glioblastoma; Neural stem cell
Mesh:
Year: 2015 PMID: 26314280 PMCID: PMC5436904 DOI: 10.1016/j.ymeth.2015.08.013
Source DB: PubMed Journal: Methods ISSN: 1046-2023 Impact factor: 3.608